Turnstone Biologics (TSBX) Stock Price, News & Analysis

Company Overview

Turnstone Biologics, Inc. (NASDAQ: TSBX) is a clinical-stage biopharmaceutical company pioneering next-generation viral immunotherapies for the treatment of solid tumors. The company’s proprietary platform harnesses engineered oncolytic viruses to selectively infect and lyse cancer cells while simultaneously delivering genetic payloads that stimulate a potent anti-tumor immune response. By combining direct tumor debulking with immune modulation, Turnstone aims to address cancers that have demonstrated resistance to conventional therapies.

Turnstone’s pipeline includes multiple clinical-stage candidates targeting a range of solid tumor indications. Lead programs leverage distinct viral backbones engineered to carry immunostimulatory cytokines, bispecific T-cell engagers or immune checkpoint modulators. These investigational therapies are currently being evaluated in Phase 1/2 trials for hepatocellular carcinoma, pancreatic cancer and virus-associated malignancies such as HPV+ head and neck squamous cell carcinoma. Early-stage assets in preclinical development explore next-generation constructs designed to improve tumor targeting and expand the reach of the platform.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Turnstone Biologics completed its merger with a special purpose acquisition company in early 2021 and began trading on the Nasdaq under the ticker symbol TSBX. The company is led by an experienced management team with deep expertise in oncology drug development, virology and translational medicine. Turnstone collaborates with leading academic institutions and leverages global clinical trial networks to advance its mission of delivering durable, virus-based immunotherapies to patients with high-unmet-need tumors.

Key Stats

• Today's Range: $0.36 to $0.36
• 50-Day Range: $0.35 to $0.37
• 52-Week Range: $0.29 to $2.42
• Volume: N/A
• Average Volume: 142,319 shs
• Market Capitalization: $8.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.40
• Consensus Rating: Reduce

TSBX Stock Analysis - Frequently Asked Questions

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) released its earnings results on Friday, August, 8th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.08.

When did Turnstone Biologics IPO?

Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share.

What other stocks do shareholders of Turnstone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSBX
• CIK: 1764974
• Web: turnstonebio.com
• Phone: 347-897-5988
• Fax: N/A
• Employees: 82
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Turnstone Biologics: $0.40
• High Price Target: $0.40
• Low Price Target: $0.40
• Potential Upside/Downside: +12.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -171.86%
• Return on Assets: -128.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.33
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $19.31 million
• Price / Sales: 0.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 23,140,000
• Free Float: 15,713,000
• Market Cap: $8.21 million
• Optionable: Not Optionable
• Beta: 1.36